Medications for Hemophilia B

7 results

  • Alhemo (concizumab)

    (concizumab)
    Novo Nordisk
    Usage: Alhemo is indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency with inhibitors) and hemophilia B (factor IX deficiency with inhibitors).

  • Alprolix

    (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    Usage: ALPROLIX is indicated for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis in adults and children with hemophilia B. It is not intended for inducing immune tolerance.

  • Benefix (coagulation factor ix (recombinant))

    (coagulation factor ix (recombinant))
    Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC
    Usage: BeneFIX® is indicated for adults and children with hemophilia B for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce bleeding frequency. It is not intended for immune tolerance induction in hemophilia B patients.

  • Beqvez (fidanacogene elaparvovec-dzkt)

    (fidanacogene elaparvovec-dzkt)
    Pfizer Laboratories Div Pfizer Inc
    Usage: BEQVEZ is a gene therapy for adults with moderate to severe hemophilia B, indicated for those on factor IX prophylaxis, experiencing life-threatening hemorrhages or serious spontaneous bleeding, and without neutralizing antibodies to AAVRh74var capsid, based on FDA-approved diagnostics.

  • Hympavzi (marstacimab-hncq)

    (marstacimab-hncq)
    Pfizer Laboratories Div Pfizer Inc
    Usage: HYMPAVZI is used for routine prophylaxis to prevent or reduce bleeding episodes in adults and pediatric patients aged 12 and older with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), both without inhibitors.

  • Profilnine (factor ix complex)

    (factor ix complex)
    GRIFOLS USA, LLC
    Usage: Profilnine (Factor IX Complex) is indicated for preventing and controlling bleeding in patients with factor IX deficiency (hemophilia B). It is not indicated for factor VII deficiency treatment.

  • Sevenfact (coagulation factor viia recombinant human)

    (Coagulation Factor VIIa Recombinant Human)
    Laboratoire Français du Fractionnement et des Biotechnologies Société Anonyme (LFB S.A.)
    Usage: SEVENFACT is indicated for treating and controlling bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B with inhibitors. It is not indicated for patients with congenital Factor VII deficiency.